From Barron's 8-25-07: Buy - Price 6.50 on Aug. 21 by Needham & Co. Target price: $10. Anesiva's [recent] announcement that the Food and Drug Administration has granted approval for Zingo...for reduction of pain associated with venous-access procedures in three-to-18-year-olds. A 700-patient adult trial is under way; results expected in 4Q07....The announcement...is a positive development, yet we await more detail in September from management regarding the commercialization timeline. Zingo is ANSV's first product to be approved by the FDA, [but] we encourage investors to also monitor...leading ANSV pain candidate 4975, now in Phase-2 development for potential use in...post-operative pain and osteoarthritis.

From Barron's 8-25-07: Outperform - Price 66.72 on Aug. 21 by Bear Stearns We are revising our 2007 diluted earnings-per-share estimate from $7.16 to $5 to reflect Capital One's decision to close its wholesale-mortgage-banking unit, GreenPoint Mortgage...the company has determined that the current mortgage environment makes it virtually impossible for the business to operate profitably...At least there will no longer be uncertainty regarding GreenPoint's prospects...Maintaining 100 price target.

From Barron's 8-25-07: Buy - Price 17.25 on Aug. 21 by Lazard Capital Markets Market cap: $1.3 billion. L-1 Identity Solutions received a seven-year contract with an estimated value of more than $11 million from the State of Montana to provide a digital driver's license issuance system...integrating appointment scheduling, automated driver's license knowledge and skills testing, digital driver's license and identification-card production, image-based facial recognition services, automated authentication of applicant identity documents, and identity-adjudication-workflow software...[This] reinforces our thesis that contract values will likely increase if REAL ID is implemented, as additional features will drive incremental contract revenue...Our target is 22, which equates to 19.5 times our 2008 Ebitda estimate.

From Barron's 8-25-07: Buy - Price 5.85 on Aug. 21 by Think Equity We are incrementally more positive on Real after a recent report that Viacom's (VIA) MTV digital-music arm, Urge, is potentially set to merge into a joint venture with Real, using Verizon Wireless for mobile distribution. With RNWK shares trading at 8.5 times enterprise value/'07earnings before interest, taxes, depreciation and amortization, and the market assigning only $2.85 per share of enterprise value over its approximately $3 in net cash per share, RNWK remains extremely attractive at current levels, especially [the] potential partnership, which could drive broader consumer awareness of Rhapsody music service. Target: 11.

From Barron's 8-25-07: Buy - Price 5.75 on Aug. 21 by Signal Hill Initiating coverage with Buy. We believe the company is well-positioned to benefit from positive momentum in the market [for learning programs in schools]...An updating of the product has improved adherence to protocols and thus increased effectiveness for middle schoolers. A redesign for elementary grades is in the research and development pipeline...Consolidation in the curriculum-content sector has placed digital-content executives in charge of the largest K-12 basal publisher, which we think increases the chances that SCIL could be acquired...A growth multiple of 20 times-25 times against our calendar-year '09 EPS target of 37 cents could yield returns ranging between 30% and 60% over 12 months.

From Barron's 8-25-07: Outperform - Price 11.17 on Aug. 21 by William Blair & Co. Initiating coverage of SGEN, which is focused on the development of antibody therapies for difficult-to-treat cancer indications, with Outperform and company profile of aggressive growth. [We] estimate that SGEN, with four clinical candidates in early- and mid-stage development, will have significant visibility over next two years...Lead candidate SGN-40 is partnered with Genentech under a collaboration that potentially could pay more than $800 million in milestone payments in addition to royalties.

From Barron's 8-25-07: Market Outperform - Price 11.75 on Aug. 21 by JMP Securities Starlims is a leading provider of laboratory-information-management systems. With the leading Web-based product in the space, Starlims is benefiting as laboratories worldwide seek to replace legacy and custom LIMS systems with commercial, Web-based solutions. Our 14 target implies a 2008 [price/earnings ratio] of 17, in line with the peer-group median; target represents 19% upside from current levels.